Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 9/2007

01-09-2007 | Original Article

Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon

Authors: Antonio Tursi, Giovanni Brandimarte, Gian Marco Giorgetti, Walter Elisei, Fabio Aiello

Published in: International Journal of Colorectal Disease | Issue 9/2007

Login to get access

Abstract

Background and aims

The role of probiotics in the treatment of diverticulitis is still not known. The aim of our study was to investigate whether balsalazide and/or VSL#3 is effective in preventing diverticulitis recurrence.

Materials and methods

In this pilot study, 30 consecutive patients (19 males, 11 females, mean age 60.1 years, range 47–75 years) affected by uncomplicated diverticulitis of the colon were monitored. After obtaining remission, the patients were randomly assigned to one of the following groups as follows: group A, balsalazide 2.25 g daily for 10 days every month plus VSL#3 450 billions/day for 15 days every month and group B, VSL#3 alone 450 billions/day for 15 days every month. Primary end-point was considered the maintaining of remission throughout a 12-month follow-up. Secondary end-points considered were (1) the assessment of the overall scores at the end of the follow-up and (2) the effects of the two different treatments with regards to every symptom assessed.

Results/findings

One group A patient was withdrawn from the study at the 6th month and one group B patient was lost at the 6th month of follow-up. One group A patient (6.66%) showed relapse of symptoms at the 10th month of follow-up. At the end of follow-up, 11 patients were completely symptom-free (73.33%), whilst 2 patients complained of only mild, recurrent symptoms (13%). Two group B patients (13.33%) showed relapse of the disease at the 5th and 8th month of follow-up, respectively. At the end of follow-up, 8 patients were completely symptom-free (60%), 2 patients complained of mild, recurrent symptoms (13.33%), 1 patient (6.66%) complained of mild but continuous symptoms. No side effects were recorded throughout the follow-up in both groups.

Interpretation/conclusions

Combination probiotic/anti-inflammatory drug was found better than probiotic treatment in preventing relapse of uncomplicated diverticulitis of the colon, even if without statistical significance.
Literature
1.
2.
Painter NS, Burkitt DP (1971) Diverticular disease of the colon: a deficiency disease of western civilization. Br Med J 2:450–454PubMedCrossRef
3.
Parks TG (1975) Natural history of diverticular disease of the colon. Clin Gastroenterol 4:53–69PubMed
4.
Painter NS, Burkitt DP (1975) Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol 4:3–21PubMed
5.
Berman LG, Burdick D, Heitzman ER, Prior JT (1968) A critical reappraisal of sigmoid peridiverticulitis. Surg Gynecol Obstet 127:481–491PubMed
6.
Williams RA, Davis IP (1995) Diverticular disease of the colon. In: Haubrich WS, Schaffner F (eds) Bockus gastroenterology, 5th edn. Saunders, Philadelphia, pp 1637–1656
7.
Tursi A, Brandimarte G, Daffinà R (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Dig Liver Dis 34:510–515PubMedCrossRef
8.
Ragunath K, Williams JG (2001) Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther 15:1549–1554PubMedCrossRef
9.
Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC (2002) A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 16:61–68PubMedCrossRef
10.
Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD (2002) A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 16:69–77PubMedCrossRef
11.
Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, Crowe JP, Schofield KJ, Taylor MD (1998) Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. Aliment Pharmacol Ther 12:1207–1216PubMedCrossRef
12.
Sanders ME (1999) Probiotics. Food Technol 53:67–77
13.
Gionchetti P, Amadini C, Rizzello F, Venturi A, Palmonari V, Morselli C, Romagnoli R, Campieri M (2002) Probiotics—role in inflammatory bowel disease. Dig Liver Dis 34(Suppl 2):S58–S62PubMedCrossRef
14.
15.
Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M (2002) Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 34(Suppl 2):S48–S53PubMedCrossRef
16.
Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L et al (2002) Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side-effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 97:2744–2749PubMedCrossRef
17.
Frič P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15:313–315PubMedCrossRef
18.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W (2006) Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomised, open-label study. J Clin Gastroenterol 40:312–316PubMedCrossRef
19.
Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M (1999) Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13:1103–1108PubMedCrossRef
20.
Lamanna A, Orsi A (1984) In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 11:365–367
21.
Papi C, Ciaco A, Koch M, Capurso L (1995) Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 9:33–39PubMedCrossRef
22.
Chautems RC, Ambrosetti P, Ludwig A, Mermillod B, Morel P, Soravia C (2002) Long-term follow-up after first acute episode of sigmoid diverticulitis: is surgery mandatory?: a prospective study of 118 patients. Dis Colon Rectum 45:962–966PubMedCrossRef
23.
Brandimarte G, Tursi A (2004) Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit 10(5):PI70–PI73PubMed
24.
Shanahan F (2001) Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120:622–635PubMedCrossRef
25.
Giaccari S, Tronci S, Falconieri M, Ferrieri A (1993) Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur Rev Med Pharmacol Sci 15:29–34
26.
Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E (1999) Immunity and probiotics. Immunol Today 20:387–390PubMedCrossRef
27.
Bengmark S (1998) Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 42:2–7PubMedCrossRef
28.
Borruel N, Casellas F, Antolin M, Llopis M, Carol M, Espìin E, Naval J, Guarner F, Malagelada JR (2003) Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 98:865–870PubMedCrossRef
29.
Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A (2004) Low-dose balsalazide plus high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10:PI126–PI131PubMed
30.
Eliakim R, Rachmilewitz D (1992) Potential mediators in inflammatory bowel disease. Gastroenterology Int 5:48–56
31.
32.
33.
Gonçalves E, Almeida LM, Dinis TC (1998) Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: a synergistic interaction? Free Radic Res 29:53–66PubMedCrossRef
34.
Ulisse S, Gionchetti P, D’Alo S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C (2001) Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effect of probiotic treatment. Am J Gastroenterol 96:2691–2699PubMedCrossRef
Metadata
Title
Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon
Authors
Antonio Tursi
Giovanni Brandimarte
Gian Marco Giorgetti
Walter Elisei
Fabio Aiello
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
International Journal of Colorectal Disease / Issue 9/2007
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-007-0299-6

Other articles of this Issue 9/2007

International Journal of Colorectal Disease 9/2007 Go to the issue

Letter to the Editor

Perianal Langerhans cell histiocytosis

Letter to the Editor

Mesorectum, is it an appropiate term?

Original Article

Interleukin-18 is increased only in a minority of patients with active Crohn’s disease

Original Article

Long-term follow-up after combined fissurectomy and Botox injection for chronic anal fissures

Case Report

Parallel manifestation of Crohn’s disease and acute pericarditis: a report of two cases

Letter to the Editor

Pyogenic granuloma of the colon